skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Accurate expert analysis for a fragmented market

timely news deep insight pharma intelligence

Fast growth in the medical technology market is driven by innovation, demographic shifts, cost-efficient development and increased M&A activity. Success in this arena depends on your ability to bring cutting-edge solutions to the fore quickly, and having accurate intelligence is crucial for a sound development strategy. 


How we help

Our medtech market intelligence will keep you up-to-date with important events and help you anticipate future technology needs – so you can evaluate new market opportunities and make confident business decisions.

  • Find comprehensive and accurate information on devices/diagnostics that compete in your markets
  • Stay abreast of important current events in our space that will affect your business
  • Rapidly find information on opportunities or targets within the medtech arena
  • Stay up to date with new trends and innovation in order to evaluate opportunities as they arise


See how we can help you get ahead in the competitive medtech environment: watch the video




Relevant products


Medtech Insight: global medical technology news & analysis

You’ll instantly connect to the latest in global medtech developments with industry news, trends, deals, product developments, opinions, analysis, and context behind the headlines and more – all available at your fingertips.

Key benefits:

  • Real-time news and analysis
  • Regulatory development news
  • Company development news

Meddevicetracker: medical device intelligence and forecasts

In the continually evolving medtech competitive landscape, it is vital to stay up-to-date with key events. With Meddevicetracker, you’ll be able to anticipate upcoming filings, research clinical trial dates and data, and access market size information and expert forecasts, all in one place.

Key benefits:

  • Real-time market intelligence
  • Medical device market coverage
  • Discover new opportunities

In Vivo: strategic insights for life sciences decision-makers

In Vivo offers comprehensive coverage of the global medical industry’s competitive landscape.

Key benefits:

  • Cutting edge thought leadership
  • Expert analysis
  • Hear from news makers

Pharma Intelligence latest insights

  • Medtech Insight

    QSR Author Kim Trautman Predicts What A Mash-Up Of FDA's Quality System Regulation And ISO 13485 Might Look Like

    By Shawn M. Schmitt 17 Aug 2018

    US FDA will face high hurdles as it works to write a new rule that would merge the agency's Quality System Regulation with international quality systems standard ISO 13485. That's according to Kim Trautman, a longtime industry insider who wrote the QSR in the early to mid-1990s. "It’s a clear heavy lift from a regulatory policy perspective" that could take as long as five years to complete, she says. In the meantime, Trautman offers some insight into what device-makers might see in a new hybrid quality systems regulation from FDA. She addresses everything from corrective and preventive action (CAPA) to labeling, and complaint handling to risk management – and more.

    Topic FDA

  • Medtech Insight

    Pre-Certs, Test Groups And More: US FDA Outlines Possible New Dx Paradigm

    By Sue Darcey 17 Aug 2018

    The agency has responded to a draft diagnostics reform bill in Congress with proposed reforms that diverge some ways from the proposed legislation, but stick with the underlying goal of completely remaking how lab tests, including test kits and lab-developed tests, are regulated. The agency has put forward a proposal to establish a pre-certification process for test developers, divide most tests into high- or low-risk categories (but exempt many from pre-market review) and remove the concept of substantial equivalence.

    Topic FDA

  • In Vivo

    True Innovation In Women's Health Hindered Because Conditions Are Not Fatal

    By Lucie Ellis 17 Aug 2018

    Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.

    Topic Drug approval Drug review

  • Meddevicetracker

    Meddevicetracker Q3 2018 Outlook Report Extract

    14 Aug 2018

    In this report, we cover catalysts from 10 devices expected to occur in Q3 2018. These include important regulatory milestones and trial data across the cardiovascular, neurology,  and endocrine (including diabetes) spaces. Additionally, at the end of this report we have included a list of Large Impact catalysts through Q3 2018.

  • In Vivo

    Cancer's New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?

    By William Looney 13 Aug 2018

    The 16 million survivors of cancer in the US today form a restless constituency with its own disparate set of interests – and by sheer weight of numbers is beginning to direct changes to medical practice that pose both risks and opportunity for biopharma.

    Topic Cancer

  • Medtech Insight

    Kavanaug's Potential Rulings On ACA's 10 Essential Benefits Could Impact Medtech Coverage

    By Sue Darcey 09 Aug 2018

    An analysis of Supreme Court nominee Brett Kavanaugh’s prior rulings opposing the Affordable Care Act, and how his weight on ACA cases coming before the high court may remove some marketplace insurance for medtech products for preexisting illnesses and mental health that are currently covered. The third of a multi-part Medtech Insight feature series on what a more conservative Supreme Court could mean for future court decisions that impact the medical device industry.

    Topic Medtech

  • In Vivo

    NASH: Flying The Plane While Building It

    By Amama Sadiq, Iliyana P. Atanasova, Katherine J. Franklin 03 Aug 2018

    Drug development for nonalcoholic steatohepatitis (NASH), a form of liver disease, is a game of incomplete information: pipeline evolution is occurring in parallel with continued efforts to better understand and manage the disease. To date, no therapy for patients with NASH has been approved and consequences of the condition can be severe, including cirrhosis and hepatocellular carcinoma.

    Topic Clinical trials

  • Medtech Insight

    Higher Medtech Fees In Philippines Will Support Ongoing Regulatory Improvements

    By Ashley Yeo 31 Jul 2018

    Medtech regulatory fees in the Philippines are being increased for the first time since 2001. The country's FDA says the new fees will support quality improvements.

    Topic Policy and regulation

  • Medtech Insight

    Exec Chat: JNJ's Innovation Partnering Strategy Goes Broad And Beyond 'Pinpoint Intervention'

    By Tina Tan 31 Jul 2018

    Medtech's biggest companies are becoming more hands-on in supporting early-stage technologies; their no longer just looking to pick up ready-to-buy assets. Among the most active in this approach is Johnson & Johnson, which has established several vehicles through which it supports and scouts external innovation. Medtech Insight chats with Mirren Mandalia, senior director of new ventures and transactions for medical devices at Johnson & Johnson Innovation, to find out what is driving J&J's technology sourcing strategy and how medtech innovators can work with the diversified health care giant.

    Topic Company analysis Strategy

  • In Vivo

    Ortho Demand Pull: DePuy Synthes Shaping Its Digital And Robotic Surgery Strategy Around Patient Needs

    By Ashley Yeo 26 Jul 2018

    Johnson & Johnson's DePuy Synthes orthopedic business has taken a measured view of digital and robotic capabilities, rather than acquiring assets that perhaps do not fully meet its strategic needs. For the business's global R&D head Euan Thomson, any new technology must augment the group's abilities to drive meaningful outcomes.

    Topic Digital Health

  • Medtech Insight

    Global Approvals Infographic

    25 Jul 2018

    Meddevicetracker recorded 62 medical device approvals from outside the United States in the first quarter for 2018, including 46 CE Marks from Europe.

    Topic Medtech

  • Medtech Insight

    Pathogen-Reduction Tech Gets Some Focus At FDA Panel Meeting, But Not Enough, Cerus Says

    By Ferdous Al-Faruque 24 Jul 2018

    While a panel of US FDA experts agreed pathogen reduction technology is a promising strategy for reducing blood platelet contaminations, they raised concerns about the cost of implementing the technology. The maker of the technology, Cerus, says the panel was under-briefed and distracted.

    Topic FDA Policy and regulation

  • Medtech Insight

    Canada Consults On Mandatory Reporting Of Device Incidents By Hospitals

    By Vibha Sharma 24 Jul 2018

    The Canadian government has made it mandatory for hospitals to report medical device incidents and serious adverse reactions in their control irrespective of where these incidents originate.

    Topic Medtech

  • Medtech Insight

    Open Payments: Zimmer, Medtronic Top List Of Spenders

    By Elizabeth Orr 17 Jul 2018

    Major medical device companies paid almost $1bn in consulting fees, royalties, research costs and other expenses to physicians in 2017, the most recent data release from the US Open Payments database shows. Zimmer Biomet reported the highest spending on general physician payments, while Roche and Medtronic topped the list of research spending.

    Topic Clinical trials

  • Medtech Insight

    Compliance Corner: Follow These 4 Tips From FDA's Maisel For A Better Pre-Market Experience

    By Shawn M. Schmitt 17 Jul 2018

    Bill Maisel – the director of the Office of Device Evaluation within US FDA's Center for Devices and Radiological Health (among other titles) – says there are four things device-makers should do to make sure they succeed during the product-review process.

    Topic Business strategies

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: